Annual General Meeting on May 28, 2020 – Decision of a closed virtual session and procedureadmin2020-05-29T15:01:04+02:00May 18th, 2020|
Availability and consultation of the information related to the Annual General Meeting to be held on May 28, 2020admin2020-07-31T10:52:12+02:00May 11th, 2020|
Pixium Vision extends its cash runway with the issue of € 1.25 million new tranche from ESGO and a pre-agreed € 2.5 million French State Guaranteed Loanadmin2020-05-04T16:22:07+02:00May 4th, 2020|
Pixium Vision makes available its 2019 Universal Registration Documentadmin2020-04-24T17:19:53+02:00April 24th, 2020|
Pixium Vision strengthens scientific leadership with new senior medical and clinical advisorsadmin2020-04-23T17:51:25+02:00April 23rd, 2020|
Pixium Vision Reports Cash Position as of March 31, 2020, and provides business and financial update with cash runway extended until Q1 2021admin2020-04-17T10:26:33+02:00April 16th, 2020|
Pixium Vision announces positive follow-up data from Prima System study in dry AMDadmin2020-04-17T10:27:15+02:00March 31st, 2020|
Pixium Vision announces Prima System successful activation in first patient in USadmin2020-03-04T18:12:26+01:00March 4th, 2020|
Pixium Vision announces publication in Ophthalmology of promising Prima System data in dry AMDadmin2020-06-10T18:58:41+02:00March 2nd, 2020|
Pixium Vision announces issue of € 1.25 million new tranche from ESGO financing agreement to continue to accelerate its clinical programsadmin2020-02-18T22:07:31+01:00February 19th, 2020|
Transfer of Pixium Vision’s shares listing to Euronext Growth Parisadmin2020-02-17T16:25:46+01:00February 14th, 2020|
Pixium Vision announces 2019 full year financial results and provides business updateadmin2020-06-13T08:47:15+02:00February 13th, 2020|
